AI Science Tracker
EN

Analysis of Bladder Cancer Staging Prediction Using Deep Residual Neural Network, Radiomics, and RNA-Seq from High-Definition CT Images.

Not stated in the abstract reviewed · 30 Apr 2024 · medicine

Discovery

Analysis of Bladder Cancer Staging Prediction Using Deep Residual Neural Network, Radiomics, and RNA-Seq from High-Definition CT Images.

Source check: Source checked. Not independent scientific confirmation.

Finding: The primary full text's Methods and Results support the assigned case-specific AI-enabled result: An integrated CT, radiomics, and RNA-seq model predicted bladder-cancer stage and recurrence risk.

Technology: An integrated CT, radiomics, and RNA-seq model predicted bladder-cancer stage and recurrence risk.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
An integrated CT, radiomics, and RNA-seq model predicted bladder-cancer stage and recurrence risk.
Test and result
Results report the measured cohort/data outcome for the assigned claim: An integrated CT, radiomics, and RNA-seq model predicted bladder-cancer stage and recurrence risk. Study conclusions remain bounded to the reported setting.
Limitation / still unknown
The full text describes its data/cohort, comparison and evaluation appropriate to the represented result; the claim is limited to this study.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11074870/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.